Intra-Cellular Therapies, Inc. (ITCI)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025

Company Description

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders.

The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors.

The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.

Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies logo
Country United States
Founded 2002
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 860
CEO Sharon Mates

Contact Details

Address:
135 Route 202/206, Suite 6
Bedminster, New Jersey 07921
United States
Phone 646 440 9333
Website intracellulartherapies.com

Stock Details

Ticker Symbol ITCI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001567514
CUSIP Number 46116X101
ISIN Number US46116X1019
Employer ID 36-4742850
SIC Code 2834

Key Executives

Name Position
Dr. Sharon Mates Ph.D. Co-Founder, Chairman and Chief Executive Officer
Michael I. Halstead J.D. President
Sanjeev Narula Executive Vice President, Chief Financial Officer and Treasurer
Dr. Suresh K. Durgam M.D. Executive Vice President and Chief Medical Officer
Mark Neumann Executive Vice President and Chief Commercial Officer
Dr. Robert E. Davis Ph.D. Senior Vice President and Chief Scientific Officer
Juan Fernando Sanchez M.D. Vice President of Corporate Communications and Investor Relations
Karen Patruno Sheehy Esq. Senior Vice President and Chief Compliance Officer
John P. Condon Senior Vice President, General Counsel and Secretary
Dr. Michael Olchaskey Pharm.D. Senior Vice President and Head of Regulatory Affairs

Latest SEC Filings

Date Type Title
Apr 2, 2025 POSASR Filing
Apr 2, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 2, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 2, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 2, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 2, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 2, 2025 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Apr 2, 2025 POS AM Post-Effective amendments for registration statement
Apr 2, 2025 8-K Current Report
Apr 2, 2025 25-NSE Filing